Johnson & Johnson said the U.S. rollout of the Varipulse pulsed field ablation platform is back on after an investigation found the devices operate as intended. Can artificial intelligence (AI) ...

Heart failure doesn’t always come with loud warnings. It is therefore important to listen to your body, recognise the silent ...

The main results of the SUMMIT trial, reported last year, showed that tirzepatide—a dual glucose-dependent insulinotropic ...

Gentian Diagnostics reported a robust financial performance for Q4 2024, achieving record quarterly sales of NOK 42.6 million, marking a 14% year-over-year increase. The company's stock surged by 7.58 ...

Combination therapy with oral or inhaled treprostinil may benefit patients with pulmonary arterial hypertension and cardiovascular comorbidities.

The secondary outcomes focus on a functional (six-minute walk test) and laboratory outcome (NT-proBNP). So the outcome of this trial will really inform mosliciguat's potential in PH-ILD.

1. Toshio Nishikimi, Yasuaki Nakagawa. Potential pitfalls when interpreting plasmaBNP levels in heart failure practice. Journal of Cardiology. 2021; June 1. 2. Weber M, Hamm C. Role of B-type ...

Background and aims N-terminal pro-B-type natriuretic peptide (NT-proBNP) is a well-established biomarker in clinical practice, particularly for heart failure, but its role in predicting atrial ...

Six-minute walking distance increased significantly after 6 months of treatment (569±16 to 597±16 m, p=0.016). Serum N-terminal-prohormone brain natriuretic peptide (NT-proBNP) levels decreased ...

Diagnostic thresholds of N-terminal prohormone of brain natriuretic peptide (NT-proBNP) for heart failure with preserved ejection fraction (HFpEF) in ambulatory patients with chronic ...

For patients with chronic unexplained dyspnea seen in the outpatient setting, the optimal thresholds of plasma NT-proBNP currently used to diagnosis heart failure with preserved ejection fraction ...